Acadia Pharma Stock: Nuplazid's (Pimavanserin) Last Hurrah (NASDAQ:ACAD)
seekingalpha.com
news
2022-10-19 05:46:40

Orla/iStock via Getty Images ACADIA (NASDAQ:ACAD) is an old standby that has been a serial disappointment. In this article I discuss the past, present, and future of its once promising mega-blockbuster therapy NUPLAZID (pimavanserin, selective serotonin inverse agonist). In the dreams of bulls. That is the story; however Acadia has another round pending with the FDA. Trofinetide in treatment of Rett syndrome looks like a possible consolation prize. I will discuss it. Lastly, I take a look at Acadia's financials and how they measure up from an investment perspective.
